Global Biosimilars Market Size By Type (Recombinant Non-glycosylated Proteins (Insulin, rHGH), By Application (Oncology, Blood Disorders), By Region, And Segment Forecasts, 2023 to 2032

The Global Biosimilars Market was valued at USD 23.4 billion in 2023 and is projected to reach USD 76.8 billion by 2031, growing at a CAGR of 15.9% during the forecast period of 2023–2031. The market's robust growth is driven by increasing demand for cost-effective biologic treatments, patent expirations of blockbuster biologics, and growing investments by pharmaceutical companies in biosimilar development. Additionally, the rising prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders has increased the demand for affordable treatment options, further propelling biosimilars adoption across global healthcare systems.

Drivers:

1. Patent Expiry of Biologics:

Many high-revenue-generating biologic drugs have lost or are nearing patent expiration, paving the way for biosimilars to enter the market. This provides a significant cost-saving option for healthcare providers and boosts competition.

2. Increasing Demand for Affordable Biologics:

With rising healthcare costs and global efforts to expand access to life-saving therapies, biosimilars offer a cost-effective solution without compromising therapeutic efficacy.

3. Supportive Regulatory Environment:

Streamlined and harmonized regulatory frameworks by agencies like the FDA, EMA, and WHO are accelerating approvals and market access for biosimilars, especially in oncology, rheumatology, and endocrinology.

Restraints:

1. High Development Costs and Complexity:

Despite being more affordable than originator biologics, biosimilars require extensive clinical trials and sophisticated manufacturing capabilities, resulting in high development costs and regulatory barriers.

2. Limited Awareness and Physician Reluctance:

A lack of understanding and confidence among healthcare professionals regarding biosimilars’ efficacy and safety can slow market penetration, particularly in emerging economies.

Opportunity:

1. Expansion in Emerging Economies:

Rising healthcare infrastructure and government initiatives in countries such as India, Brazil, and China are creating strong growth opportunities for biosimilar manufacturers.

2. Growth in Oncology and Autoimmune Therapeutics:

Biosimilars targeting monoclonal antibodies for cancer and autoimmune diseases represent a significant opportunity, as these therapies constitute a large portion of biologic drug expenditures globally.

Market by System Type Insights:

Based on product type, monoclonal antibodies (mAbs) dominated the biosimilars market in 2023, contributing the highest revenue. The increasing adoption of mAbs in oncology and immunology, coupled with the launch of biosimilars for drugs like Trastuzumab and Adalimumab, is driving growth in this segment. Other key product categories include insulin biosimilars, erythropoietin, and growth hormones.

Market by End-Use Insights:

By end-use, hospital pharmacies held the largest share in 2023 due to high biosimilar usage in in-patient care, especially for chronic disease treatment regimens. Retail pharmacies and research institutes are also growing rapidly, supported by increased outpatient prescriptions and ongoing clinical studies respectively.

Market by Regional Insights:

Europe led the global biosimilars market in 2023, driven by early adoption, strong regulatory support, and successful cost-containment strategies by national healthcare systems. However, Asia-Pacific is projected to witness the fastest growth during the forecast period, fueled by increasing healthcare spending, local manufacturing capabilities, and a favorable policy landscape. North America is also expanding significantly post the introduction of the Biologics Price Competition and Innovation Act (BPCIA).

Competitive Scenario:

Key players in the global biosimilars market include:

Pfizer Inc.

Amgen Inc.

Samsung Bioepis

Sandoz (a Novartis Division)

Biocon Ltd.

Mylan N.V.

Celltrion Healthcare

Teva Pharmaceuticals

Fresenius Kabi

Coherus BioSciences

These companies are focusing on strategic alliances, accelerated clinical trials, and new product launches to strengthen their market position. For instance:

In 2023, Amgen received FDA approval for its biosimilar Amjevita (Adalimumab), making it the first Humira biosimilar to launch in the U.S.

In 2024, Biocon Biologics and Viatris announced global expansion plans after acquiring biosimilar rights for multiple biologics across oncology and immunology.

In 2025, Sandoz launched a new suite of biosimilars targeting anti-cancer monoclonal antibodies across European and Latin American markets.

Scope of Work – Global Biosimilars Market

Report Metric Details

Market Size (2023) USD 23.4 billion

Projected Market Size (2031) USD 76.8 billion

CAGR (2023–2031) 15.9%

Market Segments Product Type, End-Use, Region

Growth Drivers Patent expiration, cost savings, rising chronic disease burden

Opportunities Oncology and autoimmune therapeutics, emerging market expansion

Key Market Developments:

March 2023: Pfizer announced positive Phase III trial results for its biosimilar of Bevacizumab, expanding its oncology biosimilar pipeline.

July 2024: Celltrion received EU approval for its biosimilar Remsima SC, the first subcutaneous version of infliximab.

January 2025: Biocon launched its insulin glargine biosimilar in Japan, strengthening its Asia-Pacific footprint.

FAQs:

1) What is the current market size of the Global Biosimilars Market?

The market was valued at USD 23.4 billion in 2023.

2) What is the major growth driver of the Global Biosimilars Market?

Patent expirations of biologics and the need for cost-effective treatment options are key drivers.

3) Which is the largest region during the forecast period in the Global Biosimilars Market?

Europe led the market in 2023, but Asia-Pacific is expected to grow at the fastest rate through 2031.

4) Which segment accounted for the largest market share in Global Biosimilars Market?

Monoclonal antibodies (mAbs) accounted for the largest share in 2023.

5) Who are the key market players in the Global Biosimilars Market?

Pfizer, Amgen, Samsung Bioepis, Biocon, and Sandoz are among the key market players.